CASR and Alzheimer disease: These findings have clearly pointed out to a class of therapeutic agents, the CaSR negative allosteric modulators (NAMs), which effectively block all such AD’s pathogenetic mechanisms in untransformed cortical human neurons and astrocytes in vitro and could stop the progression of AD neuropathology in the patients (Armato et al., 2013; Chiarini et al., 2017a; Chiarini et al., 2017b).